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Neurobiological research on drugs: ethical and policy implications
Drug addiction is a behaviour
characterised by the individual
exhibiting a loss of control over their
consumption. Addicts may wish to stop,
but find it difficult to do so, despite
often experiencing negative
consequences. Modern developments
in neurobiology help us to better
understand this process. Moreover,
such developments now provide strong
scientific grounds for viewing drug
addiction as a psychiatric disorder,
usually classified as a ‘chronic and
relapsing brain disease’.
Most neurobiological research on
addiction has focused on the role a
drug-released neurotransmitter called
dopamine has on the repeated
activation of the ‘reward system’–
circuitry made up of a complex set of
cerebral structures which act as a
barometer, indicating a person’s
physical and psychological state.
Spurred on by recent technological
developments occurring rapidly in this
field, new models have arisen which
take into account the implication of
other neurotransmitters in the process,
also exploring the role of genetic
differences between individuals. By
providing a better understanding of
how addiction develops, this research
may provide the basis for new
psychological and pharmacological
treatments and prevention strategies.
The findings so far are encouraging,
but their implications can easily be
overstated or misunderstood, and also
raise a number of important ethical
issues that require careful
consideration. This paper provides
a summary of the key developments
in this area and underlines the fact that
any potential new approaches will
require rigorous evaluation for safety
and efficacy before being introduced
into routine practice.
Key issues at a glance
1.Neurobiological research tries to understand how addictive
drugs produce neurochemical changes in the brain’s
reward pathway, making their use appealing and
producing a drive to use them repeatedly.
4.Novel pharmacotherapies targeted at specific neurotransmitter
systems, pharmacological drug implants, drug vaccines or
neurological treatments may have the potential to ameliorate
addictive behaviours.
2. A growing body of research suggests that chronic drug
use can produce long-term disruptions in the modulation
of neurocognitive circuits involved in motivation and
attention, decision-making and the ability to inhibit
impulses.
5.Neuroscience and genetic research promise to provide a
detailed causal explanation in terms of brain processes.
However, causal, or over-simplified models of addiction could
also potentially lead to more coercive policies towards addicted
individuals, the neglect of important social policies, or
undermine support for existing proven approaches to drug
treatment.
3.Neuroimaging and genetic technologies may help to
define more precisely intimate mechanisms of addiction
and to identify individuals who have a vulnerability to
develop addiction, potentially allowing interventions to be
targeted at those at greater risk.
6. There is a pressing need to explore the ethical and policy
implications of addiction neuroscience research to ensure that
developments are taken forward in ways that adequately
safeguard human rights and protect the ethical values of
consent, liberty, equality and privacy.
Definitions
Neurotransmitter: a chemical produced and released by neurons. Some of these molecules (GABA, glutamic acid)
participate in the communication between neurons; some others (dopamine, noradrenaline, serotonin) modulate (amplify
or attenuate) the information.
Reward system: this brain circuit reinforces behaviour when activated. Data indicate that drugs of abuse are pleasurable
because they activate this system.
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‘Developments in neuroscience
are transforming our
understanding of how people
become addicted to drugs while
opening-up avenues of
investigation for new approaches
to treatment. We must, however,
ensure that such beneficial new
approaches are rigorously
evaluated prior to implementation
to ensure maximum success and
financial efficiency.’
Wolfgang Götz,
EMCDDA Director
Neurobiological research1.
in addiction
Almost all drugs known to induce abuse or
addiction in humans increase the release
of a neurotransmitter called dopamine
in a sub-cortical structure, the nucleus
accumbens. The cell bodies of neurons
which release dopamine are located in the
ventral tegmental area and the substantia
nigra (see figure). These dopaminergic
neurons form the meso-corticolimbic
pathway. They stimulate different cerebral
structures, such as the prefrontal cortex,
the amygdala and the hippocampus,
which are part of a circuitry called the
‘reward system’.
Most neurobiological models of addiction
argue that, because drugs of abuse release
dopamine and activate the reward system,
addiction is due to a modification of kinetic
reactions and increased dopamine release.
This dysregulation would correspond either
to an increased reactivity of dopaminergic
neurons to specific stimuli linked to the
pleasurable and addictive product or to a
down-regulation of dopamine signalling and
a dampening of activity in the reward
pathway. In natural situations, dopamine is
released when a rewarding experience is
new, better than expected or unanticipated.
This release of dopamine helps the
individual to memorise signals announcing a
reward. Hence, when the dopamine system
becomes over-aroused by drug use, pursuit
of the repetition of these effects can
dominate other important, goal-directed
activities.
New models in the2.
neurobiology of addiction
Some recent studies suggest that, despite
the critical and unquestionable role
dopamine plays in reward, drugs of abuse
may not necessarily induce addiction via a
direct effect on dopaminergic neurons.
There is some evidence that dopamine acts
downstream to two other neuromodulators,
noradrenaline and serotonin, responsible for
vigilance and for the control of impulsivity,
respectively. Animal studies indicate that
noradrenergic and serotonergic neurons are
coupled (i.e. limit the activity of each other)
and that repeated exposure to drugs of
abuse disrupts this regulation. Over time,
noradrenergic and serotonergic neurons
become autonomous and hyper-reactive to
external stimuli and arguably this drug-
induced long-term uncoupling explains
dysfunctions in motivation and in the ability
to inhibit impulses.
Animal studies and other evidence suggest
great variability in vulnerability to
addiction. New technologies mean that
neurobiological research can start to identify
neuropsychological and genetic differences
in individuals that may influence their
chances of developing addiction if they use
drugs.
New technologies in3.
addiction research
Advances in genomic and molecular
biology, such as the ability to clone and
sequence receptor subtypes, transporters
and endogenous agonists, have enabled
scientists to identify and specifically target
relevant receptor or transporter sites with
drugs that either block (antagonists) or
facilitate (agonists or partial agonists)
activity. Moreover, genetic manipulation
techniques have been used on animal
models to increase (i.e. overexpression
mutants) or block (i.e. transgenic knockouts
of dominant-negative mutants) the activity
of a specific molecule under analysis.
In humans, genetic studies have tried to
identify specific addiction susceptibility
genes. Large-scale linkage and association
studies have identified numerous promising
candidate genes that confer vulnerability to
addiction but, to date, few of these alleles
have been consistently replicated and many
of the associations are modest.
Neuroimaging, using technologies such as
functional magnetic resonance imaging
(fMRI), positron tomography (PET), single
photon emission computed tomography
(SPECT), magnetoencephalograph (MEG),
and electroencephalograph (EEG), has
provided insight into the way in which
drug-induced changes in the brain can
produce the type of cognitive deficits seen in
people addicted to drugs. These are
non-invasive techniques which may help to
identify neuropsychological deficits that may
be the primary source of an individual’s
inability to stop using drugs.
Traditional and new4.
treatments of addiction
Addiction has traditionally been treated by
a combination of pharmacological and
psychosocial treatments. Usual
pharmacological treatments include:
(i) drugs that either block the addictive drug
from working (e.g. naltrexone as a relapse
prevention of heroin dependence) or make it
unpleasant (e.g. disulfiram for alcohol
dependence) or (ii) drugs that replace the
addictive drug with a less harmful version of
the drug (e.g. opioid substitution treatment
using methadone). Nicotine replacement
therapy is a common form of substitution
treatment for smoked tobacco but is not
particularly effective. Some treatments may
also be used for a short period to help
wean individuals off all drugs. Psychosocial
interventions include cognitive behavioural
therapy, motivational interviewing, drug
counselling or 12-step support groups.
These therapies provide an important
adjunct to pharmacological and medical
treatments in achieving a long-term
successful outcome.
Progress in neurobiological research on
addiction has led to the use of drugs which
target the dopaminergic system. However,
this strategy has not yet proven effective in
treating addiction, possibly because the
wrong dopamine receptor has been
targeted (i.e. D2) or because other
modulatory neurotransmitter systems also
require consideration.
A number of other novel treatment
approaches are in development or are
being researched which may provide
new approaches to treating some forms
of drug dependence. These include
immunotherapies in the form of ‘vaccines’
against the effects of nicotine, cocaine and
heroin that act by binding to the target drug
in the bloodstream, thus preventing it from
reaching the brain. Neurosurgery is the most
invasive and permanent form of
experimental treatment, but there exist strong
ethical objections to this approach. Less
extreme but still raising ethical concerns is
deep brain stimulation which involves the
insertion of electrical stimulating electrodes
into the regions of the brain involved in
addiction, such as the insula. A less invasive
approach is transcranial magnetic
stimulation that involves placing a small
magnetic coil against an individual’s skull in
order to block or enhance neural activity.
None of these approaches are currently
proven and all bring with them potential
costs as well as possible benefits.
Causal models of addiction5.
How addiction is understood by society is
important for deciding which responses are
appropriate. The definition of addiction as a
disorder in which an individual’s control over
their drug use is impaired can be contrasted
with a historical perspective where drug
users were seen as autonomous individuals
who voluntarily engaged in illegal activities.
Even today, some authors remain sceptical
about the existence of addiction, and the
extent to which dependent individuals have
autonomy over their actions remains a
question of fundamental importance. The
brain disease model of addiction challenges
the view that drug use is always a voluntary
choice by arguing that prolonged drug use
results in long-lasting changes in the brain
structure that undermine voluntary control.
Although these brain changes may explain
why addicts continue to use drugs despite
tolerance to their pleasurable effects and
serious adverse consequences, this model
may also be used to argue that addicts may
lack the autonomy to make informed
choices or act upon them. Drug use
encompasses a complex set of behaviours
and even the autonomy of dependent
individuals is variable. One risk of an overly
simplified interpretation of the emerging
neurobiological evidence is that it could be
inappropriately used to justify coerced,
highly invasive or even damaging
treatments, by proponents overly optimistic
about their ability to cure addiction and
without showing sufficient concern for
broader human rights and ethical
implications.
Ethical and policy6.
implications
Neurobiological research can make a
significant contribution to our understanding
of the extent to which addicts are
autonomous, and therefore responsible for
their actions. The autonomy of addicts in
making choices about their drug use is
undoubtedly impaired when they are
acutely intoxicated or experiencing severe
withdrawal symptoms. However, the extent
of impairment varies greatly and informed
consent, i.e. the process by which individuals
agree to treatment in the full knowledge of
its possible risks and benefits, and without
coercion, can and should be obtained after
patient stabilisation. If neurobiological
research leads to the development of new
treatment approaches, they will join and
hopefully complement existing treatments.
Patients will need to be given information on
different treatment options, and the costs
and benefits of any new therapy should be
carefully considered along with its potential
efficacy. Treatments that are invasive or
dangerous are difficult to justify if safer
options already exist. Important ethical
considerations will surely arise if patients are
denied free choices over which treatment
they can pursue: these issues are likely to be
particularly important for treatments offered
within the criminal justice system where some
degree of coercion may be present.
A generally accepted ethical principle is
that care available in prison settings should
be equivalent to that available to the wider
community. Ethical concerns would arise if
new therapies were disproportionately
targeted on those in custody and other
treatments of proven efficacy denied.
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Note: Meso-corticolimbic dopaminergic neurons from the ventral tegmental area and substantia nigra project
to an important structure of the reward circuitry, the nucleus accumbens, and to the cortical areas primarily
responsible for making decisions, such as whether to use drugs (e.g. the prefrontal cortex, and the cingulate
gyrus). Projections from the midbrain also make connections with the caudate and the putamen (labelled
Striatum in the figure).
Source: Hyman et al., 2006.
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Conclusions and policy considerations
1. Neuroscience has the potential to improve our
understanding of addiction, possibly leading to new
forms of treatment. There is a need to continue supporting
studies in this area, whilst reviewing how European
research can be encouraged and best organised.
4. The efficacy of novel immunological approaches and
neurological techniques will require detailed scrutiny.
Some approaches in this area may be used in ways that
raise important ethical and social concerns which could
offset, or even be greater than potential benefits.
2. The assumption that repeated consumption of
drugs of abuse induces long-term modifications
in cerebral neurotransmission presents a strong
argument for research aimed at characterising
these modifications and finding ways to reverse
them.
5. Neurobiological research provides support for a ‘medical
model’ of addiction. However, many drug issues concern
the non-dependent use of illicit substances and the question
of which approaches are appropriate to encourage
addicted individuals into treatment — particularly those
who may not want to be treated — is a critical one.
3. New methodologies such as neuroimaging and genetic
research may help to better understand variations in
vulnerability to addiction, even if social factors are also
clearly important. However, the extent to which this can
be used in practice remains questionable.
6. A major challenge for policy will be to find ways
to educate the public about the neurobiological basis
of addiction, whilst acknowledging that individual
and social choices also impact on drug use
and addiction.
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